These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 37744349)

  • 1. Immunotherapy: a promising approach for glioma treatment.
    Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
    Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A scientometric analysis of immunotherapies for gliomas: Focus on GBM.
    Xing Y; Yasinjan F; Geng H; He M; Yang M; Gao Y; Zhang J; Zhang L; Guo B
    Asian J Surg; 2024 Oct; 47(10):4271-4280. PubMed ID: 38448290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.
    Linares CA; Varghese A; Ghose A; Shinde SD; Adeleke S; Sanchez E; Sheriff M; Chargari C; Rassy E; Boussios S
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
    Suryawanshi YR; Schulze AJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
    Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
    Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
    Kwok D; Okada H
    J Neurooncol; 2020 Apr; 147(2):281-295. PubMed ID: 32185647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Immunotherapeutic Approaches for Malignant Gliomas.
    Han MH; Kim CH
    Brain Tumor Res Treat; 2022 Jan; 10(1):1-11. PubMed ID: 35118842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic advances in glioma management: The rise of vaccine-based approaches.
    Andrew Awuah W; Shah MH; Tan JK; Ranganathan S; Sanker V; Darko K; Tenkorang PO; Adageba BB; Ahluwalia A; Shet V; Aderinto N; Kundu M; Abdul-Rahman T; Atallah O
    CNS Neurosci Ther; 2024 Sep; 30(9):e70013. PubMed ID: 39215399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.
    Maxwell R; Luksik AS; Garzon-Muvdi T; Lim M
    Curr Neurol Neurosci Rep; 2017 Jun; 17(6):50. PubMed ID: 28488122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects.
    Chowdhury S; Bappy MH; Clocchiatti-Tuozzo S; Cheeti S; Chowdhury S; Patel V
    Cureus; 2021 Dec; 13(12):e20604. PubMed ID: 35103180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Products for the Immunotherapy of Glioma.
    Huang Q; Pan X; Zhu W; Zhao W; Xu H; Hu K
    Nutrients; 2023 Jun; 15(12):. PubMed ID: 37375698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances and future of immunotherapy for glioblastoma.
    Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
    Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
    Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; Internò V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
    Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging immune-based technologies for high-grade gliomas.
    Giotta Lucifero A; Luzzi S
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):957-980. PubMed ID: 35924820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.